The GIST paradigm: lessons for other kinase-driven cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumour (GIST) is the most common intestinal sarcoma, often resistant to traditional treatments.
• GIST pathogenesis is linked to mutations in KIT, PDGFRA, or BRAF genes, leading to activated oncoproteins.
• Activated KIT and PDGFRA are key diagnostic and therapeutic targets in GIST.

Purpose of the Study:

• To review the targeted therapy of GISTs based on oncogenic KIT activation.
• To explore the concept of oncogene addiction in GIST and other cancers.
• To discuss mechanisms of resistance to kinase inhibitors and potential combination strategies.

Main Methods:

• Review of literature on GIST pathogenesis, targeted therapy, and resistance mechanisms.
• Analysis of clinical response data for imatinib mesylate in metastatic GIST.
• Comparison of GIST models with other oncogene-addicted cancers.

Main Results:

• Imatinib mesylate effectively treats unresectable/advanced GIST, with ~80% response/stable disease in metastatic cases.
• KIT mutation status significantly influences treatment response, enabling genotype-driven therapy.
• Resistance to imatinib can arise from secondary mutations in KIT, leading to kinase reactivation.

Conclusions:

• Targeting activated kinases like KIT is a successful strategy in GIST therapy.
• Oncogene addiction is a common theme in cancer, driving the success of targeted kinase inhibitors.
• Combination therapies, potentially involving downstream pathway inhibitors, may overcome resistance to single kinase inhibitors.